Benzinga | Apr 16, 2021 09:23AM EDT

Mersana Therapeutics Shares Quiet; Co At 8 a.m. ET Began Conference Call, Webcast To Discuss Selection Of NaPi2b Biomarker Cutoff And Commercial Diagnostic Development Path

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a conference call and webcast on Friday, April 16, 2021 at 8:00 a.m. ET to discuss the selection of the NaPi2b biomarker cutoff and the commercial diagnostic development path for the ongoing UPLIFT registration strategy in platinum-resistant ovarian cancer. The presentation will review the Company's plan to deliver a robust, predictive and reproducible commercial diagnostic assay.



To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 4598737. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.